Corcept Therapeutics (CORT) Tops Q2 EPS by 9c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $113.98 +2.11%
EPS Growth %: +393.8%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +393.8%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.09 better than the analyst estimate of $0.23. Revenue for the quarter came in at $163.8 million versus the consensus estimate of $155.22 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- BMO Capital Starts Abercrombie & Fitch (anf) at Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
